All In Biotech

Drug Trial Radar · NCT07057414

The Safety and Efficacy of GMDTC for Injection in Subjects With Elevated Cadmium Levels

Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Single-Center Clinical Study to Evaluate the Safety and Efficacy of GMDTC for Injection in Subjects With Elevated Cadmium Levels

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

22

Actual

Start

Jul 7, 2025

Primary completion

Jan 26, 2026

Study completion Mar 4, 2026

Sponsor

Lead sponsor
Guangdong Jianersheng Pharmaceutical Technology Co., Ltd.Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Guangdong Provincial Hospital for Occupational Disease Prevention and Treatment
First posted
Jul 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, single-center Phase IIa clinical study.

Conditions

  • Cadmium Exceeds the Standard

Interventions

  • GMDTC for injectionDrug

    GMDTC for Injection with a specification of 0.5g/vial, and administered by intravenous infusion. According to the drug preparation SOP , Using 0.9% physiological saline to achieve the required concentration for each dose group (Dose Group 1: 2 g reconstituted in 500 mL, final concentration 4 mg/mL; Dose Group 2: 1.5 g reconstituted in 500 mL , final concentration 3 mg/mL). All infusion-related reactions must be documented. Drug preparation must be performed by an non-blind investigator independent of the study to maintain blinding integrity for other study personnel.

  • 0.9% Sodium Chloride Injection(0.9% NaCl)Other

    0.9% Sodium Chloride Injection with a specification of 500mL/bag, and administered by intravenous infusion. The infusion volume should be equal in volume to the corresponding investigational drug at the same dose in the experimental group. All infusion-related reactions must be documented. Drug preparation must be performed by a non-blind investigator independent of the study to maintain blinding integrity for other study personnel.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacodynamic Parameters , 24-hour urinary cadmiumTime frame: Evaluated at pre-dose (Day-1) and post-dose (Day1-Day6, Day8-Day13)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Guangdong Provincial Hospital for Occupational Disease Prevention and Treatment

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.